Dr. Christian Meyer explores proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to allegedly bolster competition and enhance patient access.
EU seeks harmonisation of privilege for generic market entry, Managing IP 2025
To the publication
